Kidney Week

Abstract: SA-PO0910

Persistent Urinary Metabolic Risk in Hispanic Patients with Kidney Stone Disease: A Mexican Cohort Study

Session Information

• Health Maintenance, Nutrition, and Metabolism
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Health Maintenance, Nutrition, and Metabolism

• 1500 Health Maintenance, Nutrition, and Metabolism

Authors

• Sánchez Maure, Michelle, Centro Medico Nacional 20 de Noviembre, Mexico City, CDMX, Mexico

Michelle Sánchez Maure, MD

• Delgado, Daniel Alberto, Centro Medico Nacional 20 de Noviembre, Mexico City, CDMX, Mexico

Daniel Alberto Delgado, MD

• Salazar Hurtado, Jorge David, Centro Medico Nacional 20 de Noviembre, Mexico City, CDMX, Mexico

Jorge David Salazar Hurtado, MD

• De La Torre, Juana Citlali, Centro Medico Nacional 20 de Noviembre, Mexico City, CDMX, Mexico

Juana Citlali De La Torre, DM

• Lara Palafox, Oscar, Centro Medico Nacional 20 de Noviembre, Mexico City, CDMX, Mexico

Oscar Lara Palafox, MD, PhD

• Ayala Flores, Sergio, Centro Medico Nacional 20 de Noviembre, Mexico City, CDMX, Mexico

Sergio Ayala Flores, MD

• Gomez, Ricardo, Centro Medico Nacional 20 de Noviembre, Mexico City, CDMX, Mexico

Ricardo Gomez, DO, APRN, CNN

• Gonzalez-Fuentes, Carolina, Centro Medico Nacional 20 de Noviembre, Mexico City, CDMX, Mexico

Carolina Gonzalez-Fuentes, MD, MSc

• Alamilla-Sanchez, Mario, Centro Medico Nacional 20 de Noviembre, Mexico City, CDMX, Mexico

Mario Alamilla-Sanchez, MD, MSc

Background

Kidney stone disease is a recurrent metabolic disorder associated with obesity, diabetes, and metabolic syndrome. Urinary abnormalities including hypocitraturia, low urinary volume, hypercalciuria, and high sodium are major modifiable risk factors for recurrence. However, longitudinal data on persistent urinary metabolic abnormalities in Hispanic/Latino populations remain limited.

Methods

We conducted a retrospective study of patients with kidney stone disease who underwent metabolic evaluation. Demographic data, cardiometabolic comorbidities, kidney function, serum biochemistry, and urinary metabolic parameters were analyzed at baseline and 6-month follow-up. Continuous variables were expressed as median (IQR) and categorical variables as percentages. Paired comparisons used the Wilcoxon test. Univariable logistic regression explored factors associated with hypocitraturia, while Fisher's exact and Mann-Whitney U tests assessed failure to achieve metabolic targets.

Results

A total of 43 patients were included. Median age was 62 years (50.5–69.5), and 65.1% were women. Diabetes, hypertension, obesity, and dyslipidemia were present in 37.2%, 34.9%, and 51.3% of evaluable patients, respectively. Hypocitraturia was the most frequent abnormality, identified in 78% of patients. At 6 months, 90.7% failed to achieve at least one urinary metabolic target. Urinary citrate showed no significant improvement between baseline and follow-up [204.6 (98.8–409.5) vs 254.5 (96.8–467.2) mg/day; p=0.802], while urinary sodium increased significantly over time. Higher baseline urinary sodium was inversely associated with hypocitraturia (OR 0.3 per 50-unit increase; 95% CI 0.09–0.99; p=0.048).

Conclusion

Patients with kidney stone disease demonstrated a high burden of persistent urinary metabolic risk, driven mainly by hypocitraturia and failure to achieve preventive targets. The lack of improvement in urinary citrate highlights the need for structured metabolic and nutritional interventions to reduce recurrence risk.

Acknowledgment

The authors used artificial intelligence–assisted tools exclusively for grammatical revision and language editing of the manuscript.

Funding

• Government Support – Non-U.S.